Format

Send to

Choose Destination
Nat Rev Immunol. 2007 Oct;7(10):790-802.

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Author information

1
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Tumour Immunology, Postbox 9101, Nijmegen, 6500HB, Netherlands.

Abstract

The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large-scale application of DC-based vaccination therapies.

PMID:
17853902
DOI:
10.1038/nri2173
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center